Nipocalimab cuts generalized myasthenia gravis symptoms in phase 2 trial

Nipocalimab showed evidence of dose-dependent, statistically significant symptom reductions in patients with generalized myasthenia gravis, while remaining generally safe and well-tolerated, in a phase 2 trial.
The finding in favor of the fully human monoclonal antibody comes as existing treatments for generalized myasthenia gravis are associated with persistent symptoms and side effects that limit their use, Carlo Antozzi, MD, and colleagues wrote in Neurology.
The study enrolled 68 adult patients with generalized myasthenia gravis who had inadequate response to standard-of-care therapy. While

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.